{"ticker": {"uuid": "6c317cc7-90f7-4370-b7d0-abc75a3227ae", "symbol": "IPH", "name": "Innate Pharma S.A.", "exchange": "PAR", "country": "FR", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Innate Pharma Jumps After Sobi Deal To Advance Lacutamab Into Phase 3; Appoints Markus Jensen As CMO", "summary": "(RTTNews) - Shares of Innate Pharma S.A. (IPHA), a clinical-stage company, surge over 25% after the company announced a strategic partnership with Swedish Orphan Biovitrum AB (SOBI.ST) to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study of Lacutamab, an investigational anti-KIR3DL2 antibody in cutaneous T-cell lymphoma (CTCL). Under the agreement terms, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in S\u00e9zary syndrome, and Sobi will receive exclusive global rights to commercialise lacuta", "url": "https://www.nasdaq.com/articles/innate-pharma-jumps-after-sobi-deal-advance-lacutamab-phase-3-appoints-markus-jensen-cmo", "source_name": "nasdaq.com", "published_at": "2026-08-10T10:21:29+00:00", "published_display": "10 Aug 2026 10:21", "sentiment": "positive", "sentiment_pct": 76, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.349, "duplicate_count": 1, "topics": ["Antibody Therapeutics", "Biotech", "Clinical Trials", "Partnership", "Phase 3"]}, {"title": "Sobi, Innate Join To Conduct TELLOMAK-3 Phase 3 Confirmatory Trial In Cutaneous T-cell Lymphoma", "summary": "(RTTNews) - Swedish Orphan Biovitrum AB (SOBI.ST) and Innate Pharma (IPHA, IPH, IPH.PA) have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma, a key step toward filing for accelerated approval of lacutamab in S\u00e9zary syndrome, a subtype of cutaneous T cell lymphoma. Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in S\u00e9zary syndrome. Sobi will pay Innate Pharma $75 million, payable on closing. Innate will be eligible to receive", "url": "https://www.nasdaq.com/articles/sobi-innate-join-conduct-tellomak-3-phase-3-confirmatory-trial-cutaneous-t-cell-lymphoma", "source_name": "nasdaq.com", "published_at": "2026-08-10T07:10:24+00:00", "published_display": "10 Aug 2026 07:10", "sentiment": "positive", "sentiment_pct": 59, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.267, "duplicate_count": 1, "topics": ["Biotech", "Clinical Trials", "M A", "Pharma"]}, {"title": "Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma", "summary": "STOCKHOLM, Aug. 10, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi\u00ae) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) (\"Innate\" or the \"Company\") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in S\u00e9zary syndrome, a subtype of CTCL. Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing ", "url": "https://finance.yahoo.com/healthcare/articles/sobi-enters-strategic-partnership-innate-063600544.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T06:36:00+00:00", "published_display": "10 Aug 2026 06:36", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.163, "duplicate_count": 2, "topics": ["Biotech", "Cancer", "Clinical Trials", "Partnership", "Rare Diseases"]}], "by_tier": {"direct": [{"title": "Innate Pharma Jumps After Sobi Deal To Advance Lacutamab Into Phase 3; Appoints Markus Jensen As CMO", "summary": "(RTTNews) - Shares of Innate Pharma S.A. (IPHA), a clinical-stage company, surge over 25% after the company announced a strategic partnership with Swedish Orphan Biovitrum AB (SOBI.ST) to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study of Lacutamab, an investigational anti-KIR3DL2 antibody in cutaneous T-cell lymphoma (CTCL). Under the agreement terms, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in S\u00e9zary syndrome, and Sobi will receive exclusive global rights to commercialise lacuta", "url": "https://www.nasdaq.com/articles/innate-pharma-jumps-after-sobi-deal-advance-lacutamab-phase-3-appoints-markus-jensen-cmo", "source_name": "nasdaq.com", "published_at": "2026-08-10T10:21:29+00:00", "published_display": "10 Aug 2026 10:21", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 76, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.349, "duplicate_count": 1, "topics": ["Antibody Therapeutics", "Biotech", "Clinical Trials", "Partnership", "Phase 3"]}, {"title": "Sobi, Innate Join To Conduct TELLOMAK-3 Phase 3 Confirmatory Trial In Cutaneous T-cell Lymphoma", "summary": "(RTTNews) - Swedish Orphan Biovitrum AB (SOBI.ST) and Innate Pharma (IPHA, IPH, IPH.PA) have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma, a key step toward filing for accelerated approval of lacutamab in S\u00e9zary syndrome, a subtype of cutaneous T cell lymphoma. Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in S\u00e9zary syndrome. Sobi will pay Innate Pharma $75 million, payable on closing. Innate will be eligible to receive", "url": "https://www.nasdaq.com/articles/sobi-innate-join-conduct-tellomak-3-phase-3-confirmatory-trial-cutaneous-t-cell-lymphoma", "source_name": "nasdaq.com", "published_at": "2026-08-10T07:10:24+00:00", "published_display": "10 Aug 2026 07:10", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 59, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.267, "duplicate_count": 1, "topics": ["Biotech", "Clinical Trials", "M A", "Pharma"]}, {"title": "Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma", "summary": "STOCKHOLM, Aug. 10, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi\u00ae) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) (\"Innate\" or the \"Company\") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in S\u00e9zary syndrome, a subtype of CTCL. Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing ", "url": "https://finance.yahoo.com/healthcare/articles/sobi-enters-strategic-partnership-innate-063600544.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T06:36:00+00:00", "published_display": "10 Aug 2026 06:36", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.163, "duplicate_count": 2, "topics": ["Biotech", "Cancer", "Clinical Trials", "Partnership", "Rare Diseases"]}], "industry": [], "sector": []}, "total_fetched": 4, "total_unique": 3, "total_relevant": 3, "pipeline_health": {"providers_attempted": 1, "providers_with_results": 1, "provider_counts": {"eodhd": 4}, "raw_articles": 4, "unique_stories": 3, "duplicates_removed": 1, "relevant_stories": 3, "current_evidence": 3, "direct_evidence": 3, "eodhd_articles": 3, "eodhd": {"configured": true, "status": "healthy", "calls_used": 255, "call_budget": 500, "budget_used_pct": 51.0, "requests_made": 51, "last_success_at": "2026-08-13T08:31:40.249917+00:00", "newest_seen_at": "2026-08-13T08:28:00+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 3289, "unmapped_mentions": 1836}, "status": "healthy"}, "sentiment_summary": {"positive": 3, "negative": 0, "neutral": 0, "score": 60, "raw_score": 68, "total": 3, "evidence_count": 3, "effective_articles": 2.76, "direct_story_count": 3, "industry_story_count": 0, "sector_story_count": 0, "story_count": 3, "source_count": 2, "source_concentration": 0.6698, "direct_share": 100, "dispersion": 7, "confidence": 60, "evidence_status": "measured", "score_version": "evidence-v4", "newest_article_at": "2026-08-10T10:21:29+00:00", "label": "Constructive news tone", "tone": "positive"}, "classifier": {"primary_event": "deals", "primary_label": "Deals and strategy", "confidence": 66, "events": [{"event": "deals", "label": "Deals and strategy", "weight": 1.2, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.6, "count": 1}], "positive_events": 3, "negative_events": 0, "pipeline": {"providers_attempted": 1, "providers_with_results": 1, "provider_counts": {"eodhd": 4}, "raw_articles": 4, "unique_stories": 3, "duplicates_removed": 1, "relevant_stories": 3, "current_evidence": 3, "direct_evidence": 3, "eodhd_articles": 3, "eodhd": {"configured": true, "status": "healthy", "calls_used": 255, "call_budget": 500, "budget_used_pct": 51.0, "requests_made": 51, "last_success_at": "2026-08-13T08:31:40.249917+00:00", "newest_seen_at": "2026-08-13T08:28:00+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 3289, "unmapped_mentions": 1836}, "status": "healthy"}}, "market_context": {"has_market_context": true, "latest_close": 1.51, "latest_week": "2026-08-07", "one_week_move": -2.8, "four_week_move": -4.2, "twelve_week_move": -13.3, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.376271, "market_dynamics_buy_signal": false, "relative_strength": -9.072915, "fair_value_gap": -21.0, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 44.4681, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.8% over one week, -4.2% over four weeks, trend active, and below fair value."}, "interpretation": {"label": "Positive news being faded", "tone": "negative", "classification": "positive_rejected", "summary": "Constructive headlines are not being rewarded by price, which raises a rejection flag.", "confidence": 63, "badges": ["Sentiment confirms active trend", "Value support"], "opportunities": ["Constructive tone aligns with the Sharemaestro trend signal.", "Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Deals and strategy", "sentiment_word": "constructive"}, "charts": {"sources": [{"label": "nasdaq.com", "count": 2}, {"label": "finance.yahoo.com", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 3}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Deals and strategy", "count": 2}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "60/100", "tone": "positive", "text": "Constructive news tone"}, {"label": "Evidence confidence", "value": "60/100", "tone": "neutral", "text": "2.76 effective stories after overlap and weighting."}, {"label": "Market reaction", "value": "Positive news being faded", "tone": "negative", "text": "Constructive headlines are not being rewarded by price, which raises a rejection flag."}, {"label": "Primary event", "value": "Deals and strategy", "tone": "positive", "text": "66/100 classification confidence."}, {"label": "Company focus", "value": "3", "tone": "positive", "text": "100% of weighted evidence is company-specific."}, {"label": "Evidence agreement", "value": "7/100", "tone": "positive", "text": "lower dispersion means the independent stories agree more closely."}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-2.8% over one week, -4.2% over four weeks, trend active, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Innate Pharma Jumps After Sobi Deal To Advance Lacutamab Into Phase 3; Appoints Markus Jensen As CMO"}], "updated_at": "2026-08-13T08:40:10.035474+00:00", "detail_intelligence": {"headline": "Positive news being faded", "summary": "Constructive news tone is drawn from 3 fresh independent stories, including 3 company-specific items across 2 publishers.", "status": "measured", "metrics": [{"label": "Weighted tone", "value": 60, "display": "60", "tone": "positive", "note": "Constructive news tone"}, {"label": "Evidence confidence", "value": 60, "display": "60", "tone": "neutral", "note": "solid confidence"}, {"label": "Company focus", "value": 100, "display": "100%", "tone": "positive", "note": "3 direct stories"}, {"label": "Evidence agreement", "value": 93, "display": "93", "tone": "positive", "note": "7/100 dispersion"}], "confidence_drivers": [{"label": "Sample depth", "value": 34, "note": "2.76 effective stories"}, {"label": "Source breadth", "value": 40, "note": "2 independent publishers"}, {"label": "Direct relevance", "value": 100, "note": "company-specific evidence share"}, {"label": "Freshness", "value": 59, "note": "recency-weighted evidence"}, {"label": "Agreement", "value": 93, "note": "cross-story consistency"}, {"label": "Source independence", "value": 33, "note": "lower publisher concentration"}], "freshness": 59, "source_independence": 33, "timeline": [{"date": "2026-07-24", "label": "24 Jul", "count": 0, "score": null, "tone": "neutral", "x": 42.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-25", "label": "25 Jul", "count": 0, "score": null, "tone": "neutral", "x": 87.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-26", "label": "26 Jul", "count": 0, "score": null, "tone": "neutral", "x": 133.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-27", "label": "27 Jul", "count": 0, "score": null, "tone": "neutral", "x": 179.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-28", "label": "28 Jul", "count": 0, "score": null, "tone": "neutral", "x": 225.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-29", "label": "29 Jul", "count": 0, "score": null, "tone": "neutral", "x": 271.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-30", "label": "30 Jul", "count": 0, "score": null, "tone": "neutral", "x": 316.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-31", "label": "31 Jul", "count": 0, "score": null, "tone": "neutral", "x": 362.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-01", "label": "01 Aug", "count": 0, "score": null, "tone": "neutral", "x": 408.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-02", "label": "02 Aug", "count": 0, "score": null, "tone": "neutral", "x": 454.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-03", "label": "03 Aug", "count": 0, "score": null, "tone": "neutral", "x": 500.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-04", "label": "04 Aug", "count": 0, "score": null, "tone": "neutral", "x": 545.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-05", "label": "05 Aug", "count": 0, "score": null, "tone": "neutral", "x": 591.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-06", "label": "06 Aug", "count": 0, "score": null, "tone": "neutral", "x": 637.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-07", "label": "07 Aug", "count": 0, "score": null, "tone": "neutral", "x": 683.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-08", "label": "08 Aug", "count": 0, "score": null, "tone": "neutral", "x": 729.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-09", "label": "09 Aug", "count": 0, "score": null, "tone": "neutral", "x": 774.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-10", "label": "10 Aug", "count": 3, "score": 68, "tone": "positive", "x": 820.6, "y": 102.2, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-08-11", "label": "11 Aug", "count": 0, "score": null, "tone": "neutral", "x": 866.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-12", "label": "12 Aug", "count": 0, "score": null, "tone": "neutral", "x": 912.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-13", "label": "13 Aug", "count": 0, "score": null, "tone": "neutral", "x": 958.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}], "timeline_points": "820.6,102.2", "timeline_has_signal": true, "timeline_start": "24 Jul", "timeline_mid": "03 Aug", "timeline_end": "13 Aug", "momentum": {"label": "Improving", "tone": "positive", "recent_score": 76, "prior_score": 62, "delta": 14, "recent_count": 1, "prior_count": 2, "volume_delta": -1}, "freshness_buckets": [{"label": "Last 24 hours", "count": 0, "share": 0}, {"label": "1 to 3 days", "count": 1, "share": 33}, {"label": "4 to 7 days", "count": 2, "share": 67}, {"label": "8 to 30 days", "count": 0, "share": 0}], "source_profile": [{"label": "nasdaq.com", "count": 2, "share": 67, "score": 69, "tone": "positive"}, {"label": "finance.yahoo.com", "count": 1, "share": 33, "score": 66, "tone": "positive"}], "event_profile": [{"label": "Deals and strategy", "count": 2, "share": 67, "score": 62, "tone": "positive"}, {"label": "Regulatory and legal", "count": 1, "share": 33, "score": 76, "tone": "positive"}], "topics": [{"label": "Clinical Trials", "count": 3, "share": 100}, {"label": "Biotech", "count": 3, "share": 100}, {"label": "Partnership", "count": 2, "share": 67}, {"label": "Rare Diseases", "count": 1, "share": 33}, {"label": "Phase 3", "count": 1, "share": 33}, {"label": "Pharma", "count": 1, "share": 33}, {"label": "M A", "count": 1, "share": 33}, {"label": "Cancer", "count": 1, "share": 33}, {"label": "Antibody Therapeutics", "count": 1, "share": 33}], "supporting": [{"label": "Direct evidence", "text": "3 current stories are mapped specifically to IPH."}, {"label": "Narrative agreement", "text": "Cross-story agreement is 93/100, indicating a comparatively coherent tape."}], "tempering": [{"label": "Source breadth", "text": "Only 2 publishers currently contribute to the measured read."}, {"label": "Price disagreement", "text": "Constructive headlines are not being rewarded by price, which raises a rejection flag."}], "supporting_heading": "What supports the read", "tempering_heading": "What tempers the read", "latest_observation": {"title": "Innate Pharma Jumps After Sobi Deal To Advance Lacutamab Into Phase 3; Appoints Markus Jensen As CMO", "summary": "(RTTNews) - Shares of Innate Pharma S.A. (IPHA), a clinical-stage company, surge over 25% after the company announced a strategic partnership with Swedish Orphan Biovitrum AB (SOBI.ST) to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study of Lacutamab, an investigational anti-KIR3DL2 antibody in cutaneous T-cell lymphoma (CTCL). Under the agreement terms, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in S\u00e9zary syndrome, and Sobi will receive exclusive global rights to commercialise lacuta", "url": "https://www.nasdaq.com/articles/innate-pharma-jumps-after-sobi-deal-advance-lacutamab-phase-3-appoints-markus-jensen-cmo", "source_name": "nasdaq.com", "published_at": "2026-08-10T10:21:29+00:00", "published_display": "10 Aug 2026 10:21", "sentiment": "positive", "sentiment_pct": 76, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.349, "duplicate_count": 1, "topics": ["Antibody Therapeutics", "Biotech", "Clinical Trials", "Partnership", "Phase 3"]}, "article_count": 3, "updated_at": "2026-08-13T08:40:10.035474+00:00"}, "price_sentiment_path": {"available": true, "price_points": [{"x": 42.0, "y": 116.4, "label": "13 Feb 2026", "close": 1.47, "index": 100.0}, {"x": 78.6, "y": 130.2, "label": "20 Feb 2026", "close": 1.41, "index": 95.8}, {"x": 115.3, "y": 117.3, "label": "27 Feb 2026", "close": 1.46, "index": 99.7}, {"x": 151.9, "y": 133.8, "label": "06 Mar 2026", "close": 1.39, "index": 94.7}, {"x": 188.6, "y": 165.0, "label": "13 Mar 2026", "close": 1.25, "index": 85.1}, {"x": 225.2, "y": 204.2, "label": "20 Mar 2026", "close": 1.07, "index": 73.2}, {"x": 261.8, "y": 198.4, "label": "27 Mar 2026", "close": 1.1, "index": 74.9}, {"x": 298.5, "y": 184.6, "label": "03 Apr 2026", "close": 1.16, "index": 79.2}, {"x": 335.1, "y": 184.6, "label": "10 Apr 2026", "close": 1.16, "index": 79.2}, {"x": 371.8, "y": 136.9, "label": "17 Apr 2026", "close": 1.38, "index": 93.7}, {"x": 408.4, "y": 193.9, "label": "24 Apr 2026", "close": 1.12, "index": 76.3}, {"x": 445.0, "y": 176.1, "label": "01 May 2026", "close": 1.2, "index": 81.7}, {"x": 481.7, "y": 164.1, "label": "08 May 2026", "close": 1.25, "index": 85.4}, {"x": 518.3, "y": 55.8, "label": "15 May 2026", "close": 1.74, "index": 118.5}, {"x": 555.0, "y": 78.1, "label": "22 May 2026", "close": 1.64, "index": 111.7}, {"x": 591.6, "y": 84.3, "label": "29 May 2026", "close": 1.61, "index": 109.8}, {"x": 628.2, "y": 100.4, "label": "05 Jun 2026", "close": 1.54, "index": 104.9}, {"x": 664.9, "y": 95.5, "label": "12 Jun 2026", "close": 1.56, "index": 106.4}, {"x": 701.5, "y": 85.2, "label": "19 Jun 2026", "close": 1.61, "index": 109.5}, {"x": 738.2, "y": 92.3, "label": "26 Jun 2026", "close": 1.58, "index": 107.4}, {"x": 774.8, "y": 72.7, "label": "03 Jul 2026", "close": 1.66, "index": 113.4}, {"x": 811.4, "y": 92.8, "label": "10 Jul 2026", "close": 1.57, "index": 107.2}, {"x": 848.1, "y": 107.5, "label": "17 Jul 2026", "close": 1.51, "index": 102.7}, {"x": 884.7, "y": 89.7, "label": "24 Jul 2026", "close": 1.59, "index": 108.2}, {"x": 921.4, "y": 97.7, "label": "31 Jul 2026", "close": 1.55, "index": 105.7}, {"x": 958.0, "y": 107.5, "label": "07 Aug 2026", "close": 1.51, "index": 102.7}], "sentiment_points": [{"x": 715.9, "y": 130.0, "label": "21 Jun 2026", "score": 50}, {"x": 717.1, "y": 130.0, "label": "21 Jun 2026", "score": 50}, {"x": 721.1, "y": 130.0, "label": "22 Jun 2026", "score": 50}, {"x": 721.5, "y": 130.0, "label": "22 Jun 2026", "score": 50}, {"x": 721.8, "y": 130.0, "label": "22 Jun 2026", "score": 50}, {"x": 727.5, "y": 130.0, "label": "23 Jun 2026", "score": 50}, {"x": 733.5, "y": 130.0, "label": "25 Jun 2026", "score": 50}, {"x": 746.8, "y": 133.7, "label": "27 Jun 2026", "score": 48}, {"x": 759.0, "y": 135.5, "label": "29 Jun 2026", "score": 47}, {"x": 759.4, "y": 135.5, "label": "30 Jun 2026", "score": 47}, {"x": 764.4, "y": 133.7, "label": "01 Jul 2026", "score": 48}, {"x": 766.6, "y": 133.7, "label": "01 Jul 2026", "score": 48}, {"x": 772.4, "y": 135.5, "label": "02 Jul 2026", "score": 47}, {"x": 777.6, "y": 133.7, "label": "03 Jul 2026", "score": 48}, {"x": 778.4, "y": 133.7, "label": "03 Jul 2026", "score": 48}, {"x": 780.6, "y": 133.7, "label": "04 Jul 2026", "score": 48}, {"x": 809.7, "y": 130.0, "label": "09 Jul 2026", "score": 50}, {"x": 827.8, "y": 130.0, "label": "13 Jul 2026", "score": 50}, {"x": 827.9, "y": 130.0, "label": "13 Jul 2026", "score": 50}, {"x": 839.5, "y": 130.0, "label": "15 Jul 2026", "score": 50}, {"x": 856.7, "y": 130.0, "label": "18 Jul 2026", "score": 50}, {"x": 857.2, "y": 130.0, "label": "18 Jul 2026", "score": 50}, {"x": 862.7, "y": 130.0, "label": "19 Jul 2026", "score": 50}, {"x": 862.9, "y": 130.0, "label": "19 Jul 2026", "score": 50}, {"x": 871.7, "y": 130.0, "label": "21 Jul 2026", "score": 50}, {"x": 886.5, "y": 130.0, "label": "24 Jul 2026", "score": 50}, {"x": 924.8, "y": 130.0, "label": "31 Jul 2026", "score": 50}, {"x": 952.7, "y": 130.0, "label": "05 Aug 2026", "score": 50}], "price_path": "42.0,116.4 78.6,130.2 115.3,117.3 151.9,133.8 188.6,165.0 225.2,204.2 261.8,198.4 298.5,184.6 335.1,184.6 371.8,136.9 408.4,193.9 445.0,176.1 481.7,164.1 518.3,55.8 555.0,78.1 591.6,84.3 628.2,100.4 664.9,95.5 701.5,85.2 738.2,92.3 774.8,72.7 811.4,92.8 848.1,107.5 884.7,89.7 921.4,97.7 958.0,107.5", "sentiment_path": "715.9,130.0 717.1,130.0 721.1,130.0 721.5,130.0 721.8,130.0 727.5,130.0 733.5,130.0 746.8,133.7 759.0,135.5 759.4,135.5 764.4,133.7 766.6,133.7 772.4,135.5 777.6,133.7 778.4,133.7 780.6,133.7 809.7,130.0 827.8,130.0 827.9,130.0 839.5,130.0 856.7,130.0 857.2,130.0 862.7,130.0 862.9,130.0 871.7,130.0 886.5,130.0 924.8,130.0 952.7,130.0", "price_change": 2.7, "sentiment_change": 0, "latest_close": 1.51, "start_label": "13 Feb", "mid_label": "15 May", "end_label": "07 Aug"}, "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}